Avenue Therapeutics (ATXI) Competitors $0.84 +0.02 (+1.89%) As of 09/15/2025 02:33 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATXI vs. HOOK, MRKR, GOVX, MBIO, PHXM, SNSE, ERNA, APM, ALBT, and IMCCShould you be buying Avenue Therapeutics stock or one of its competitors? The main competitors of Avenue Therapeutics include HOOKIPA Pharma (HOOK), Marker Therapeutics (MRKR), GeoVax Labs (GOVX), Mustang Bio (MBIO), PHAXIAM Therapeutics (PHXM), Sensei Biotherapeutics (SNSE), Ernexa Therapeutics (ERNA), Aptorum Group (APM), Avalon GloboCare (ALBT), and IM Cannabis (IMCC). These companies are all part of the "pharmaceutical products" industry. Avenue Therapeutics vs. Its Competitors HOOKIPA Pharma Marker Therapeutics GeoVax Labs Mustang Bio PHAXIAM Therapeutics Sensei Biotherapeutics Ernexa Therapeutics Aptorum Group Avalon GloboCare IM Cannabis HOOKIPA Pharma (NASDAQ:HOOK) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Which has stronger earnings & valuation, HOOK or ATXI? Avenue Therapeutics has lower revenue, but higher earnings than HOOKIPA Pharma. Avenue Therapeutics is trading at a lower price-to-earnings ratio than HOOKIPA Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHOOKIPA Pharma$9.35M1.21-$43.50M-$5.85-0.16Avenue TherapeuticsN/AN/A-$10.38M-$0.95-0.88 Do analysts rate HOOK or ATXI? HOOKIPA Pharma currently has a consensus target price of $4.50, suggesting a potential upside of 383.87%. Given HOOKIPA Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe HOOKIPA Pharma is more favorable than Avenue Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HOOKIPA Pharma 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer HOOK or ATXI? In the previous week, HOOKIPA Pharma had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for HOOKIPA Pharma and 0 mentions for Avenue Therapeutics. HOOKIPA Pharma's average media sentiment score of 1.00 beat Avenue Therapeutics' score of 0.00 indicating that HOOKIPA Pharma is being referred to more favorably in the media. Company Overall Sentiment HOOKIPA Pharma Positive Avenue Therapeutics Neutral Do institutionals and insiders have more ownership in HOOK or ATXI? 63.9% of HOOKIPA Pharma shares are held by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are held by institutional investors. 3.3% of HOOKIPA Pharma shares are held by company insiders. Comparatively, 1.8% of Avenue Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is HOOK or ATXI more profitable? Avenue Therapeutics has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. HOOKIPA Pharma's return on equity of -120.09% beat Avenue Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets HOOKIPA Pharma-785.66% -120.09% -77.14% Avenue Therapeutics N/A -471.57%-296.50% Which has more risk & volatility, HOOK or ATXI? HOOKIPA Pharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.07, meaning that its stock price is 107% less volatile than the S&P 500. SummaryHOOKIPA Pharma beats Avenue Therapeutics on 11 of the 15 factors compared between the two stocks. Get Avenue Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXI vs. The Competition Export to ExcelMetricAvenue TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.66M$840.61M$5.79B$10.18BDividend YieldN/A4.84%5.73%4.61%P/E Ratio0.051.1474.8626.39Price / SalesN/A26.51543.67125.97Price / CashN/A19.5625.8129.91Price / Book0.446.6613.256.28Net Income-$10.38M-$4.13M$3.29B$270.38M7 Day Performance-6.02%1.76%0.07%1.89%1 Month Performance46.58%8.04%4.60%6.01%1 Year Performance-70.05%27.75%72.95%25.26% Avenue Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXIAvenue Therapeutics1.2212 of 5 stars$0.84+1.9%N/A-70.3%$2.66MN/A0.054Gap DownHOOKHOOKIPA Pharma3.0744 of 5 stars$0.92+2.2%$4.50+389.3%-81.4%$11.21M$9.35M-0.16160Positive NewsShort Interest ↓Gap DownMRKRMarker Therapeutics3.6421 of 5 stars$0.85-2.7%$13.17+1,447.2%-65.9%$11.01M$6.59M-0.6260Short Interest ↑GOVXGeoVax Labs1.7894 of 5 stars$0.69-1.2%$8.50+1,133.7%-75.8%$10.98M$3.95M-0.3410News CoverageShort Interest ↑MBIOMustang Bio1.0274 of 5 stars$1.47+8.1%N/A-88.3%$10.64MN/A-0.02100Positive NewsGap UpPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049SNSESensei Biotherapeutics4.7005 of 5 stars$8.25+4.0%$55.00+566.7%-18.5%$10.40MN/A-0.3940Positive NewsShort Interest ↓ERNAErnexa Therapeutics0.9824 of 5 stars$1.27+2.0%N/A-94.8%$9.70M$580K-0.1510APMAptorum Group0.7682 of 5 stars$1.80+5.3%N/A-31.9%$9.63M$430K0.0030Short Interest ↑ALBTAvalon GloboCare1.1138 of 5 stars$2.50+5.9%N/A-30.7%$9.60M$1.33M-0.135News CoverageAnalyst DowngradeShort Interest ↑IMCCIM Cannabis0.9107 of 5 stars$1.79-3.2%N/A-15.7%$9.40M$39.44M-3.31340Positive NewsShort Interest ↓Gap Down Related Companies and Tools Related Companies HOOKIPA Pharma Alternatives Marker Therapeutics Alternatives GeoVax Labs Alternatives Mustang Bio Alternatives PHAXIAM Therapeutics Alternatives Sensei Biotherapeutics Alternatives Ernexa Therapeutics Alternatives Aptorum Group Alternatives Avalon GloboCare Alternatives IM Cannabis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXI) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avenue Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avenue Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATXI Stock Alerts